(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
Why this Iranian island looks like Mars after it rains- The most effective method to Engage in Local area Making arrangements for 5G Pinnacle Establishments
- Find the Historical backdrop of the Modern Unrest: Changing Society and Innovation
- Your kid wants it now. What saying yes, no or not yet teaches kids about money and instant gratification.
- Language Learning Applications for Voyagers
- Red Sea arena: Yemen’s Houthis open fourth front in Iran war, with global implications
- Vote In favor of Your #1 Compelling Female Producer
- Taylor Momsen explains why she quit 'Gossip Girl': 'I really didn't want to be there'
- California officials warn against foraging wild mushrooms after deadly poisoning outbreak
